Recent updates to asthma guidelines suggest that treatments may be used ‘as needed’ in certain patient populations. Additionally, newer monoclonal antibodies are providing an alternative to systemic glucocorticoids for severe asthma control and exacerbation prevention. The rapid release of multiple agents and changes to national/international guidelines requires a review of asthma management. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.